S*BIO completes enrollment in SB1518 JAK2 inhibitor Taper off 2 clinical trials representing myelofibrosis
S*BIO Pte Ltd today announced that it has completed enrollment of patients in two disconnected Point of view 2 clinical trials for the purpose its valid and orally-active JAK2 inhibitor SB1518 at multiple clinical sites in the U.S. and Australia with a view the treatment of myelofibrosis (MF).
These two multi-center, single-arm, open-label studies are designed to figure the efficacy and protection of SB1518 in patients with MF. Based on the clinical text derived from the Off 1 crack, 400mg orally years regularly was selected as the recommended portion in the service of the Stage 2 studies.
"Encouraging statistics from the Juncture 1 trials of SB1518 allowed us to at full speed happening into Aspect 2 studies," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "We completed the enrollment of our Development 2 studies in a apart from patch of occasion which farther demonstrates the notable behalf in SB1518 not at most from the medical community but also from the patients. This marks another worthy milestone repayment for S*BIO."
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
